Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts

Gerald L Denardo, Linda A. Kroger, Claude F. Meares, Carol M Richman, Qansy Salako, Sui Shen, Kathleen R. Lamborn, James J. Peterson, Laird A. Miers, Gao Ren Zhong, Sally J. DeNardo

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Radioimmunotherapy using 131I-ChL6 antibody has shown promise in patients with breast cancer. To enhance this potential, a novel ChL6 immunoconjugate that is catabolizable and tightly binds 90Y and 111In was developed. The immunoconjugate, 1,4,7,10-tetraazacyclododecane- N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, consists of the macrocyclic chelator DOTA linked to ChL6 by a peptide that is preferentially catabolized in the liver. The pharmacokinetic and dosimetric properties of the radioimmunoconjugates (RICs) 111In- and 90Y-DOTA-peptide-ChL6 and 111In- and 90Y-2-iminothiolane (2-IT)-2-[p-(bromoacetamido)benzyl]- DOTA-ChL6 were compared in athymic mice bearing HBT3477 human breast cancer xenografts. Each of the RICs was stable in vivo and concentrated well in the xenografts. Liver concentration, cumulative radioactivity (activity over time), and radiation dose of the DOTA-peptide-ChL6 RICs were one-third to one-half of those of the corresponding 2-IT-2-[p(bromoacetamido)benzyl]- DOTA-ChL6 RICs. Indium-111 RICs were imperfect tracers for corresponding 90Y RICs, although their pharmacokinetics and radiation dosimetries were similar. The re- suits of this study were consistent with previously published in vitro data, which indicated that the peptide linker of DOTA- peptide-ChL6 was catabolized by cathepsin B. The cumulative activities and radiation doses to the liver of DOTA-peptide-ChL6 RICs were one-half of those of corresponding RICs with the 2-IT linker. Preliminary data from pilot studies in patients with breast cancer are in accord with these observations. These novel DOTA-peptide RICs seem to have excellent clinical potential for radioimmunotherapy associated with marrow transplantation, for which liver radiation is likely to be dose limiting for 90Y.

Original languageEnglish (US)
Pages (from-to)2483-2490
Number of pages8
JournalClinical Cancer Research
Volume4
Issue number10
StatePublished - Oct 1998

Fingerprint

Immunoconjugates
Heterografts
Breast Neoplasms
Peptides
Radioimmunotherapy
Radiation
Liver
methyl 4-mercaptobutyrimidate
ChL6 monoclonal antibody
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
Pharmacokinetics
Radiometry
Cathepsin B
Indium
Chelating Agents
Nude Mice
Liver Transplantation
Radioactivity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts. / Denardo, Gerald L; Kroger, Linda A.; Meares, Claude F.; Richman, Carol M; Salako, Qansy; Shen, Sui; Lamborn, Kathleen R.; Peterson, James J.; Miers, Laird A.; Zhong, Gao Ren; DeNardo, Sally J.

In: Clinical Cancer Research, Vol. 4, No. 10, 10.1998, p. 2483-2490.

Research output: Contribution to journalArticle

Denardo, Gerald L ; Kroger, Linda A. ; Meares, Claude F. ; Richman, Carol M ; Salako, Qansy ; Shen, Sui ; Lamborn, Kathleen R. ; Peterson, James J. ; Miers, Laird A. ; Zhong, Gao Ren ; DeNardo, Sally J. / Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts. In: Clinical Cancer Research. 1998 ; Vol. 4, No. 10. pp. 2483-2490.
@article{678a593b4c934cb68d022c29f5838d1d,
title = "Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts",
abstract = "Radioimmunotherapy using 131I-ChL6 antibody has shown promise in patients with breast cancer. To enhance this potential, a novel ChL6 immunoconjugate that is catabolizable and tightly binds 90Y and 111In was developed. The immunoconjugate, 1,4,7,10-tetraazacyclododecane- N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, consists of the macrocyclic chelator DOTA linked to ChL6 by a peptide that is preferentially catabolized in the liver. The pharmacokinetic and dosimetric properties of the radioimmunoconjugates (RICs) 111In- and 90Y-DOTA-peptide-ChL6 and 111In- and 90Y-2-iminothiolane (2-IT)-2-[p-(bromoacetamido)benzyl]- DOTA-ChL6 were compared in athymic mice bearing HBT3477 human breast cancer xenografts. Each of the RICs was stable in vivo and concentrated well in the xenografts. Liver concentration, cumulative radioactivity (activity over time), and radiation dose of the DOTA-peptide-ChL6 RICs were one-third to one-half of those of the corresponding 2-IT-2-[p(bromoacetamido)benzyl]- DOTA-ChL6 RICs. Indium-111 RICs were imperfect tracers for corresponding 90Y RICs, although their pharmacokinetics and radiation dosimetries were similar. The re- suits of this study were consistent with previously published in vitro data, which indicated that the peptide linker of DOTA- peptide-ChL6 was catabolized by cathepsin B. The cumulative activities and radiation doses to the liver of DOTA-peptide-ChL6 RICs were one-half of those of corresponding RICs with the 2-IT linker. Preliminary data from pilot studies in patients with breast cancer are in accord with these observations. These novel DOTA-peptide RICs seem to have excellent clinical potential for radioimmunotherapy associated with marrow transplantation, for which liver radiation is likely to be dose limiting for 90Y.",
author = "Denardo, {Gerald L} and Kroger, {Linda A.} and Meares, {Claude F.} and Richman, {Carol M} and Qansy Salako and Sui Shen and Lamborn, {Kathleen R.} and Peterson, {James J.} and Miers, {Laird A.} and Zhong, {Gao Ren} and DeNardo, {Sally J.}",
year = "1998",
month = "10",
language = "English (US)",
volume = "4",
pages = "2483--2490",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts

AU - Denardo, Gerald L

AU - Kroger, Linda A.

AU - Meares, Claude F.

AU - Richman, Carol M

AU - Salako, Qansy

AU - Shen, Sui

AU - Lamborn, Kathleen R.

AU - Peterson, James J.

AU - Miers, Laird A.

AU - Zhong, Gao Ren

AU - DeNardo, Sally J.

PY - 1998/10

Y1 - 1998/10

N2 - Radioimmunotherapy using 131I-ChL6 antibody has shown promise in patients with breast cancer. To enhance this potential, a novel ChL6 immunoconjugate that is catabolizable and tightly binds 90Y and 111In was developed. The immunoconjugate, 1,4,7,10-tetraazacyclododecane- N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, consists of the macrocyclic chelator DOTA linked to ChL6 by a peptide that is preferentially catabolized in the liver. The pharmacokinetic and dosimetric properties of the radioimmunoconjugates (RICs) 111In- and 90Y-DOTA-peptide-ChL6 and 111In- and 90Y-2-iminothiolane (2-IT)-2-[p-(bromoacetamido)benzyl]- DOTA-ChL6 were compared in athymic mice bearing HBT3477 human breast cancer xenografts. Each of the RICs was stable in vivo and concentrated well in the xenografts. Liver concentration, cumulative radioactivity (activity over time), and radiation dose of the DOTA-peptide-ChL6 RICs were one-third to one-half of those of the corresponding 2-IT-2-[p(bromoacetamido)benzyl]- DOTA-ChL6 RICs. Indium-111 RICs were imperfect tracers for corresponding 90Y RICs, although their pharmacokinetics and radiation dosimetries were similar. The re- suits of this study were consistent with previously published in vitro data, which indicated that the peptide linker of DOTA- peptide-ChL6 was catabolized by cathepsin B. The cumulative activities and radiation doses to the liver of DOTA-peptide-ChL6 RICs were one-half of those of corresponding RICs with the 2-IT linker. Preliminary data from pilot studies in patients with breast cancer are in accord with these observations. These novel DOTA-peptide RICs seem to have excellent clinical potential for radioimmunotherapy associated with marrow transplantation, for which liver radiation is likely to be dose limiting for 90Y.

AB - Radioimmunotherapy using 131I-ChL6 antibody has shown promise in patients with breast cancer. To enhance this potential, a novel ChL6 immunoconjugate that is catabolizable and tightly binds 90Y and 111In was developed. The immunoconjugate, 1,4,7,10-tetraazacyclododecane- N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, consists of the macrocyclic chelator DOTA linked to ChL6 by a peptide that is preferentially catabolized in the liver. The pharmacokinetic and dosimetric properties of the radioimmunoconjugates (RICs) 111In- and 90Y-DOTA-peptide-ChL6 and 111In- and 90Y-2-iminothiolane (2-IT)-2-[p-(bromoacetamido)benzyl]- DOTA-ChL6 were compared in athymic mice bearing HBT3477 human breast cancer xenografts. Each of the RICs was stable in vivo and concentrated well in the xenografts. Liver concentration, cumulative radioactivity (activity over time), and radiation dose of the DOTA-peptide-ChL6 RICs were one-third to one-half of those of the corresponding 2-IT-2-[p(bromoacetamido)benzyl]- DOTA-ChL6 RICs. Indium-111 RICs were imperfect tracers for corresponding 90Y RICs, although their pharmacokinetics and radiation dosimetries were similar. The re- suits of this study were consistent with previously published in vitro data, which indicated that the peptide linker of DOTA- peptide-ChL6 was catabolized by cathepsin B. The cumulative activities and radiation doses to the liver of DOTA-peptide-ChL6 RICs were one-half of those of corresponding RICs with the 2-IT linker. Preliminary data from pilot studies in patients with breast cancer are in accord with these observations. These novel DOTA-peptide RICs seem to have excellent clinical potential for radioimmunotherapy associated with marrow transplantation, for which liver radiation is likely to be dose limiting for 90Y.

UR - http://www.scopus.com/inward/record.url?scp=0031784176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031784176&partnerID=8YFLogxK

M3 - Article

C2 - 9796981

AN - SCOPUS:0031784176

VL - 4

SP - 2483

EP - 2490

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -